Laidlaw Analyst Recommendations & Stock PicksView the latest stock recommendations issued by analysts at Laidlaw. This page tracks publicly reported analyst upgrades and downgrades, buy/hold/sell ratings, and price target changes for publicly traded companies. All data is compiled from credible public sources and updated regularly to reflect new insights from Laidlaw's equity research team. MarketBeat is not affiliated with or endorsed by Laidlaw.Updated 4/15/2026 Brokerage RankingSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROITotal Ratings5 Last 12 MonthsBuy Ratings4 Last 12 MonthsSell Ratings0 Last 12 MonthsCompanies Covered5 Last 12 Months Country All Countries USA (NYSE & NASDAQ)USA (All Exchanges)CanadaUnited Kingdom Sector All Sectors AerospaceAuto/Tires/TrucksBasic MaterialsBusiness ServicesCommunication ServicesComputer and TechnologyConstructionConsumer CyclicalConsumer DefensiveConsumer DiscretionaryConsumer GoodsConsumer StaplesEnergyFinanceFinancial ServicesIndustrialsManufacturingMedicalMiscellaneousMulti-Sector ConglomeratesReal EstateRetail/WholesaleServicesTransportationUtilities Market Cap All MarketCaps Mega Cap (More Than $200B)Large Cap ($10B-$200B)Mid Cap ($2B-$10B)Small Cap ($300M-$2B)Micro Cap ($50M-$300M)Nano Cap (Under $50M) MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.Available with a MarketBeat All Access SubscriptionMarketRank™Upgrade to All Access to use the All Ranks Filter Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.Available with a MarketBeat All Access SubscriptionMedia SentimentUpgrade to All Access to use the All Sentiments Filter Analyst consensus is the average investment recommendation among Wall Street research analysts.Available with a MarketBeat All Access SubscriptionAnalyst ConsensusUpgrade to All Access to use the All Ratings Filter Reporting Date Full History Latest Per Company Show All Ratings Strong Buy Buy Hold Sell Rating All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Price Target Change Action Any Change Raised 5%+ Raised 10%+ Raised 20%+ Lowered 5%+ Lowered 10%+ Lowered 20%+ Price Target Change Export CompanyCurrent PriceReport DateAnalystActionPrice TargetRating12-Month Recommendation ROIDetailsKZIANovogen$13.66+3.7%4/15/2026Yale JenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated Coverage$25.00Buy00.00%View details for Laidlaw rating of Novogen (NASDAQ:KZIA) on 4/15/2026PTNPalatin Technologies$14.88+3.1%12/12/2025Yale JenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated Coverage$60.00Buy00.00%View details for Laidlaw rating of Palatin Technologies (NYSEAMERICAN:PTN) on 12/12/2025FEMYFemasys$0.44+29.9%11/20/2025Yale JenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated Coverage$6.50Buy00.00%View details for Laidlaw rating of Femasys (NASDAQ:FEMY) on 11/20/2025SNTISenti Biosciences$0.99+0.3%6/6/2025Yale JenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated Coverage$5.00Buy00.00%View details for Laidlaw rating of Senti Biosciences (NASDAQ:SNTI) on 6/6/2025SLNOSoleno Therapeutics$53.013/27/2025Yale JenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost Price Target$75.00 ➝ $105.00Buy00.00%View details for Laidlaw rating of Soleno Therapeutics (NASDAQ:SLNO) on 3/27/2025NVCTNuvectis Pharma$10.35-5.4%3/17/2025Yale JenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated Coverage$19.00Buy00.00%View details for Laidlaw rating of Nuvectis Pharma (NASDAQ:NVCT) on 3/17/2025LFWDLifeward$7.05+11.2%2/10/2025Yale JenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated Coverage$120.00Buy00.00%View details for Laidlaw rating of Lifeward (NASDAQ:LFWD) on 2/10/2025ABVXAbivax$121.99-1.6%7/29/2024 Initiated Coverage$48.00Buy00.00%View details for Laidlaw rating of Abivax (NASDAQ:ABVX) on 7/29/2024INABIN8bio$1.67-0.6%3/18/2024 Initiated Coverage$225.00Buy00.00%View details for Laidlaw rating of IN8bio (NASDAQ:INAB) on 3/18/2024CINGCingulate$4.47-5.7%12/22/2023 DowngradeBuy ➝ Hold00.00%View details for Laidlaw rating of Cingulate (NASDAQ:CING) on 12/22/2023 Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. TCRTAlaunos Therapeutics$2.42+2.1%8/15/2023 DowngradeBuy ➝ Hold00.00%View details for Laidlaw rating of Alaunos Therapeutics (NASDAQ:TCRT) on 8/15/2023NCELNLS Pharmaceutics$3.16-0.6%9/6/2022 Initiated Coverage$60.00Buy00.00%View details for Laidlaw rating of NLS Pharmaceutics (NASDAQ:NCEL) on 9/6/2022CINGCingulate$4.47-5.7%1/20/2022 Initiated Coverage$170.00Buy00.00%View details for Laidlaw rating of Cingulate (NASDAQ:CING) on 1/20/2022CRISCuris$0.50+2.3%7/29/2020 Initiated Coverage$100.00Buy00.00%View details for Laidlaw rating of Curis (NASDAQ:CRIS) on 7/29/2020SLNOSoleno Therapeutics$53.016/5/2020Yale JenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated Rating$150.00Buy00.00%View details for Laidlaw rating of Soleno Therapeutics (NASDAQ:SLNO) on 6/5/2020DCTHDelcath Systems$11.02-3.8%6/1/2020 Initiated Coverage$19.00Buy00.00%View details for Laidlaw rating of Delcath Systems (NASDAQ:DCTH) on 6/1/2020ALDXAldeyra Therapeutics$1.55-2.5%5/26/2020 Reiterated Rating$30.00Buy00.00%View details for Laidlaw rating of Aldeyra Therapeutics (NASDAQ:ALDX) on 5/26/2020SLNOSoleno Therapeutics$53.0112/23/2019Francois BriseboisSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageBuy00.00%View details for Laidlaw rating of Soleno Therapeutics (NASDAQ:SLNO) on 12/23/2019EYPTEyepoint Pharmaceuticals$12.93+1.2%11/4/2019 Initiated Coverage$500.00Buy00.00%View details for Laidlaw rating of Eyepoint Pharmaceuticals (NASDAQ:EYPT) on 11/4/2019TLSATiziana Life Sciences$1.48+1.4%9/10/2019Francois BriseboisSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet Price Target$20.00Buy00.00%View details for Laidlaw rating of Tiziana Life Sciences (NASDAQ:TLSA) on 9/10/2019EBSEmergent Biosolutions$8.49+1.4%9/4/2019Francois BriseboisSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet Price Target$72.00Buy00.00%View details for Laidlaw rating of Emergent Biosolutions (NYSE:EBS) on 9/4/2019SLNOSoleno Therapeutics$53.017/8/2019 Initiated Coverage$150.00Buy00.00%View details for Laidlaw rating of Soleno Therapeutics (NASDAQ:SLNO) on 7/8/2019HOTHHoth Therapeutics$0.69+7.8%5/20/2019 Initiated Coverage$250.00Buy00.00%View details for Laidlaw rating of Hoth Therapeutics (NASDAQ:HOTH) on 5/20/2019SDEVStablecoin Development$1.41-4.7%3/13/2019 DowngradeBuy ➝ Hold00.00%View details for Laidlaw rating of Stablecoin Development (NYSEAMERICAN:SDEV) on 3/13/2019ARCTArcturus Therapeutics$7.03+0.1%2/19/2019 Initiated CoverageBuy00.00%View details for Laidlaw rating of Arcturus Therapeutics (NASDAQ:ARCT) on 2/19/2019TLSATiziana Life Sciences$1.48+1.4%12/17/2018 Initiated CoverageBuy00.00%View details for Laidlaw rating of Tiziana Life Sciences (NASDAQ:TLSA) on 12/17/2018VKTXViking Therapeutics$30.89+0.7%6/1/2018 Boost Price Target$10.00 ➝ $15.00Buy00.00%View details for Laidlaw rating of Viking Therapeutics (NASDAQ:VKTX) on 6/1/2018FENCAdherex Technologies$9.93-0.4%11/29/2017 Initiated Coverage$22.00Buy00.00%View details for Laidlaw rating of Adherex Technologies (NASDAQ:FENC) on 11/29/2017FRXFennec PharmaceuticalsC$13.69+0.7%11/29/2017 Initiated CoverageC$22.00Buy00.00%View details for Laidlaw rating of Fennec Pharmaceuticals (TSE:FRX) on 11/29/2017SDEVStablecoin Development$1.41-4.7%11/15/2017 Lower Price Target$1,750.00 ➝ $1,400.00Buy00.00%View details for Laidlaw rating of Stablecoin Development (NYSEAMERICAN:SDEV) on 11/15/2017EYPTEyepoint Pharmaceuticals$12.93+1.2%11/8/2017 Initiated Coverage$500.00Buy00.00%View details for Laidlaw rating of Eyepoint Pharmaceuticals (NASDAQ:EYPT) on 11/8/2017IONSIonis Pharmaceuticals$75.56-0.3%8/14/2017 Reiterated Rating$65.00Buy00.00%View details for Laidlaw rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 8/14/2017SDEVStablecoin Development$1.41-4.7%3/27/2017 Initiated Coverage$1,750.00Buy00.00%View details for Laidlaw rating of Stablecoin Development (NYSEAMERICAN:SDEV) on 3/27/2017OPKOPKO Health$1.27-0.8%1/3/2017 Reiterated Rating$22.00 ➝ $19.00Buy00.00%View details for Laidlaw rating of OPKO Health (NASDAQ:OPK) on 1/3/2017IONSIonis Pharmaceuticals$75.56-0.3%12/27/2016 Boost Price Target$59.00 ➝ $65.00Buy00.00%View details for Laidlaw rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 12/27/2016AXONAxon Enterprise$386.00-1.0%12/20/2016 Initiated Coverage$7.50Sell00.00%View details for Laidlaw rating of Axon Enterprise (NASDAQ:AXON) on 12/20/2016VKTXViking Therapeutics$30.89+0.7%8/11/2016 Lower Price Target$20.00 ➝ $10.00Buy00.00%View details for Laidlaw rating of Viking Therapeutics (NASDAQ:VKTX) on 8/11/2016OPKOPKO Health$1.27-0.8%8/13/2015 Initiated Coverage$22.00Buy00.00%View details for Laidlaw rating of OPKO Health (NASDAQ:OPK) on 8/13/2015OPKOPKO Health$1.27-0.8%8/12/2015 Initiated Coverage$22.00Buy00.00%View details for Laidlaw rating of OPKO Health (NASDAQ:OPK) on 8/12/2015ALDXAldeyra Therapeutics$1.55-2.5%1/26/2015Yale JenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated Coverage$30.00Buy00.00%View details for Laidlaw rating of Aldeyra Therapeutics (NASDAQ:ALDX) on 1/26/2015Your book is inside (Ad)The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.Download your copy now.IONSIonis Pharmaceuticals$75.56-0.3%12/9/2014 Boost Price Target$65.0000.00%View details for Laidlaw rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 12/9/2014IONSIonis Pharmaceuticals$75.56-0.3%11/25/2014 Reiterated RatingBuy00.00%View details for Laidlaw rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 11/25/2014IONSIonis Pharmaceuticals$75.56-0.3%8/12/2014 Initiated Coverage$52.00Buy00.00%View details for Laidlaw rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 8/12/2014IOVAIovance Biotherapeutics$4.11+11.1%6/30/2014 Initiated CoverageBuy00.00%View details for Laidlaw rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 6/30/2014SSYSStratasys$9.02+5.7%3/7/2014 Initiated Coverage$145.00Buy00.00%View details for Laidlaw rating of Stratasys (NASDAQ:SSYS) on 3/7/2014OMCLOmnicell$44.41+1.5%3/5/2014 Boost Price Target$29.00 ➝ $34.00Buy00.00%View details for Laidlaw rating of Omnicell (NASDAQ:OMCL) on 3/5/2014OMCLOmnicell$44.41+1.5%1/28/2014 Boost Price Target$27.00 ➝ $29.00Buy00.00%View details for Laidlaw rating of Omnicell (NASDAQ:OMCL) on 1/28/2014 MarketBeat Community Rating for LaidlawMarketBeat's community ratings are surveys of what our community members think about Laidlaw and other research firms in the last 90 days. Vote "Outperform" if you believe Laidlaw's recommendations will outperform the broader market over the long term. Vote "Underperform" if you believe Laidlaw's recommendations will underperform the broader market over the long term. You may vote once every thirty days. Log in to vote on this brokerage. COMMUNITY RATINGS2.6out of 5 (last 90 days)2.6 of 5 stars OUTPERFORM VOTES 30 Believe will outperform the market UNDERPERFORM VOTES 27 Believe will underperform the market Laidlaw Stock Coverage by SectorLaidlaw concentrates its research most heavily in Medical (80.0%) and Manufacturing (20.0%). The chart below shows how Laidlaw's 5 rated companies are distributed across all 2 sectors it covers.Medical4 companies80.0%Manufacturing1 company20.0%Best & Worst CallsBest Call0000.0%NASDAQ:CRISInitiated Coverage • Jul 29, 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%NASDAQ:BLPHInitiated Coverage • May 9, 2023Subscribe to MarketBeat All Access to get analyst recommendation ROI.Similarly Rated FirmsZephirin GroupRodman & RenshawNordea Equity ResearchMaxim GroupBrean CapitalSEB Equity ResearchClarus SecuritiesBloom BurtonShore Capital GroupCOCollins Stewart Laidlaw - Frequently Asked Questions What stocks does Laidlaw currently recommend buying? Laidlaw's analysts currently have buy-equivalent ratings on 4 companies. What sectors does Laidlaw specialize in? Laidlaw has the deepest coverage in Medical (80.0% of rated companies) and Manufacturing (20.0% of rated companies). How often does Laidlaw change its stock ratings? Laidlaw issued 5 ratings over the last 12 months across 5 companies — an average of roughly 0 rating actions per month. These include downgrade and initiated coverage. MarketBeat tracks every rating change as it's published so you can see the most current Laidlaw analyst actions. Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenJefferies Financial GroupWeiss RatingsUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.The Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
